Genmab — Juni 2019
-
Jazz her er Novods Key upside risks: "A restart of the solid tumour trials after review of the data;
faster-than-expected approval of MAIA 1L MM label expansion; failure of
competing CAR-T drugs in MM; strong early-stage pipeline data and potential
M&A with Genmab as a target."
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind
